A role for TGFβ and B cells in immunologic tolerance after intravenous injection of soluble antigen

Transplantation

Volumn 72, Issue 4, 2001, Pages 685-693

  Valujskikh, Anna ^a   VanBuskirk, Anne M ^b   Orosz, Charles G ^b   Heeger, Peter S ^a,c  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; CD4 ANTIGEN; MONOCLONAL ANTIBODY; RECOMBINANT INTERLEUKIN 2; TRANSFORMING GROWTH FACTOR BETA; ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; GRAFT REJECTION; HUMORAL IMMUNITY; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IN VITRO STUDY; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN GRAFT; ANIMAL; B LYMPHOCYTE; BAGG ALBINO MOUSE; C57BL MOUSE; GENETICS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; LEUKAPHERESIS; METHODOLOGY; MOUSE MUTANT; PHYSIOLOGY; SKIN TRANSPLANTATION; SOLUBILITY; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS; B-LYMPHOCYTES; BETA-GALACTOSIDASE; FEMALE; GRAFT REJECTION; IMMUNE TOLERANCE; IMMUNOLOGIC MEMORY; INJECTIONS, INTRAVENOUS; LEUKAPHERESIS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; SKIN TRANSPLANTATION; SOLUBILITY; TRANSFORMING GROWTH FACTOR BETA;

EID: 0035959006     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200108270-00022     Document Type: Article

References (59)

1. Infectious tolerance
2. Antigen persistence and time of T-cell tolerization determine the efficacy of tolerization protocols for prevention of skin graft rejection
3. Enhanced type 2 and diminished type 1 cytokines in neonatal tolerance
4. Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection
5. Induction of donor specific transplantation tolerance to cardiac allografts following treatment with nondepleting (RIB 5/2) or depleting (OX-38) anti-CD4 mAb plus intrathymic or intravenous donor alloantigen
6. Induction of transplantation tolerance by intravenous injection of allogeneic lymphocytes across an H-2 class II mismatch: Different mechanisms operate in tolerization across an H-2 class I vs. H-2 class II disparity
7. Route of antigen administration for tolerance production
8. Antigen recognition by T cells. II. Intravenous administration of native or denatured ovalbumin results intolerance to both forms of the antigen
9. Peripheral tolerance in T cell receptor-transgenic mice: Evidence for T cell anergy
10. Induction of peripheral tolerance with peptide-specific anergy in experimental autoimmune neuritis
11. Anergy of antigen-specific T lymphocytes is a potent mechanism of intravenously induced tolerance
12. Intravenous injection of soluble antigen induces thymic and peripheral T-cells apoptosis
13. Chronic intravenous injections of antigen induce and maintain tolerance in T cell receptor-transgenic mice
14. Effect of timing of intravenous administration of myelin basic protein on the induction of tolerance in experimental allergic encephalomyelitis
15. Bolus injection of aqueous antigen leads to a high density of T-cell-receptor ligand in the spleen, transient T-cell activation and anergy induction
16. Characterization and manipulation of T cell immunity to skin grafts expressing a transgenic minor antigen
17. T cells reactive to a single immunodominant self-restricted allopeptide induce skin graft rejection in mice
18. Induction of TH1 and TH2 immunity in neonatal mice
19. + T cells
20. High-resolution characterization of cytokine-producing alloreactivity in naive and allograft-primed mice
21. Contributions of direct and indirect T cell alloreactivity during allograft rejection in mice
22. TH1 and TH2 cells: Different patterns of lymphokine secretion lead to different functional properties
23. Immunological non-responsiveness and acquisition of tolerance in relation to immune privilege in the eye
24. A critical role for transforming growth factor-beta in donor transfusion-induced allograft tolerance
25. Transforming growth factor-beta and interleukin-10 subvert alloreactive delayed type hypersensitivity in cardiac allograft acceptor mice
26. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo
27. T-cell unresponsiveness in vivo and in vitro: Fine specificity of induction and molecular characterization of the unresponsive state
28. Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo
29. "Infectious" transplantation tolerance
30. + T cells in the induction of tolerance to class I molecules
31. Comprehensive assessment determinant specificity, frequency, and cytokine signature of the primed CD8 cell repertoire induced by a minor transplantation antigen
32. B cells turn off virgin but not memory T cells
33. Resting B cells as tolerogens in vivo but only for minor histocompatibility antigens: Evidence for activation of resting B cells in vivo
34. Donor resting B cells induce indefinite prolongation of fully allogeneic cardiac grafts when delivered with anti-immunoglobulin-D monoclonal antibody: Evidence for tolerogenicity of donor resting B cells in vivo
35. B lymphocytes regulate dendritic cell (DC) function in vivo: Increased interleukin 12 production by DCs from B cell-deficient mice results in T helper cell type 1 deviation
36. FcR cross-linking on monocytes results in impaired T cell stimulatory capacity
37. A first or dominant immunization. II. Induced immunoglobulin carries transforming growth factor beta and suppresses cytolytic T cell responses to unrelated alloantigens
38. Cutting edge: TGF-beta inhibits Th type 2 development through inhibition of GATA-3 expression
39. Regulation of immune responses by TGF-beta
40. Transforming growth factor beta in tissue fibrosis
41. Inhibition of cytokine production by cyclosporin A and transforming growth factor beta
42. + T lymphocytes: Inhibition by transforming growth factor-beta
43. Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha
44. + T cells requires the coordinate action of interleukin-12 and interferon-gamma and is inhibited by transforming growth factor-beta
45. Regulation of IFN-gamma and IL-10 synthesis in vivo, as well as continuous antigen exposure, is associated with tolerance to murine skin allografts
46. Inactivation of Th1 and Th2 cells by feeding ovalbumin
47. A role for transforming growth factor-beta in the veto mechanism in transplant tolerance
48. Transforming growth factor-beta-induced inhibition of T cell function: Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state
49. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease
50. Early-onset multifocal inflammation in the transforming growth factor beta 1-null mouse is lymphocyte mediated
51. Regulatory T cell clones induced by oral tolerance: Suppression of autoimmune encephalomyelitis
52. Oral tolerance to myelin basic protein induces regulatory TGF-beta-secreting T cells in Peyer's patches of SJL mice
53. IL-4 is a differentiation factor for transforming growth factor-beta secreting Th3 cells and oral administration of IL-4 enhances oral tolerance in experimental allergic encephalomyelitis
54. + T cells
55. Rat renal allograft tolerance is associated with local TGF-beta and absence of IL-2r expression within chimeric immunocytic foci
56. Alloreactive delayed-type hypersensitivity in graft recipients: Complexity of responses and divergence from acute rejection
57. Cardiac allograft tolerance: Failure to develop in interleukin-4-deficient mice correlates with unusual allosensitization patterns
58. Evidence that the continued presence of the organ graft and not peripheral donor microchimerism is essential for maintenance of tolerance to alloantigen in vivo in anti-CD4 treated recipients
59. Cytokines and peripheral tolerance to alloantigen